Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...
Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore ...
Novo Nordisk executive Dave Moore touted high interest in Wegovy's oral version of its injectable GLP-1 weight-loss ...
Eli Lilly is riding the wave of a booming weight management market. Eli Lilly's tirzepatide, sold under the brand names ...
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical ...
Wall Street's major averages took weekly gains, with both the S&P 500 and the Dow achieving new all-time high closes as the key jobs report came in line with expectations, and the U.S. Supreme Court ...
Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback